Onconick's Technology Platform
From Molecular Target to Effective ADC
How it works
Targeted Therapy: ADC (Antibody-Drug Conjugate)
Preclinical Integrated ADC Platform
stage 01
Defining the Molecular Target
Proprietary methodology for identifying promising targetable cancer-specific biomarkers
Focus on underexplored therapeutic areas
Evaluation of available target biology data, along with preclinical and/or clinical data
Ensuring proper intellectual property protection
stage 02
Production of Recombinant Proteins
Design and production of recombinant proteins for generating specific antibodies
Precise characterization of obtained proteins
stage 03
Selection and Production
of Antibodies
Precise selection methods for acquiring high-affinity antibodies with desired functionality for chosen targets
Optimized antibody production ensures full control over quality and expected properties
stage 04
Generation of highly effective antibody-drug conjugates (ADCs) achieved through precisely selected combinations of target, specific antibodies and cytotoxic compounds
Optimization of ADCs for specific clinical indications
Leading Program
ON-01: A First-in-Class ADC Therapy Targeting a High-Value Oncogenic Driver
Status: in full preclinical evaluation
By leveraging a key oncogenic driver—targeted for the first time with ADC technology—ON-01 represents a highly differentiated therapeutic approach for lung and breast cancer, with potential expansion into other hard-to-treat malignancies.
Therapeutic area
Dedicated to treating lung cancer and breast cancer
Potential to expand indications to other cancer types
Key strengths
World's first ADC therapy targeting model receptor
Innovative ADC format scFvFc
Intellectual property protected with filed patent application
Freedom to Operate confirmed by renowned patent attorneys and legal experts
Exceptionally promising preclinical results
Pre-clinical research
In vitro efficacy: confirmed across various types of lung and breast cancers
Outstanding in vivo results: complete tumor reduction in two independent lung cancer models
Safety—low toxicity
